Understanding the Science
GLP-1 products differ in the receptors they target — and therefore in how they work. Some act on a single pathway, while others combine two or three receptors, offering different mechanisms of action and different levels of weight-management support.
Product Comparison
Semaglutide, tirzepatide, and retatrutide are increasingly powerful metabolic medications that mimic gut hormones to regulate blood sugar, reduce appetite, and promote significant weight loss. They represent three progressive ‘generations’ of injectable treatments, with each targeting more hormone receptors than the last.
| Product | Semaglutide GLP-1 |
Tirzepatide GLP-1 + GIP |
Retatrutide GLP-1 + GIP + Glucagon |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Average weight reduction* | 15–17% | 20–22% | Up to 24–28.7% |
*Average weight reduction figures are drawn from clinical studies. Results vary between individuals.
GLP-1
GLP-1 is released from the intestines after eating.
- •Slows stomach emptying
- •Makes you feel full longer
- •Reduces hunger and food noise
- •Stimulates insulin release
- •Reduces glucagon secretion
GIP
GIP is another incretin hormone released after eating. For years thought less useful because people with obesity or diabetes can become resistant to it, but very powerful combined with GLP-1.
- •Boosts insulin secretion
- •May improve fat metabolism
- •May reduce nausea from GLP-1s
- •May enhance weight loss when paired with GLP-1
Glucagon
Glucagon is released when blood sugar is low. Its job is basically the opposite of insulin.
- •Tells the liver to release stored glucose
- •Increases energy expenditure
- •Can increase fat oxidation (fat burning)
- •May increase body temperature and metabolism
Combining glucagon activation with GLP-1 changes everything — GLP-1 controls appetite and blood sugar while glucagon increases energy expenditure, so together you may get less eating, more calorie burning, and potentially greater fat loss.
Other Health Benefits
Tirzepatide, semaglutide, and retatrutide offer significant health benefits beyond weight reduction, including cardiovascular protection, improved blood sugar control, and reduced substance cravings. These groundbreaking medications are increasingly recognized for their systemic impacts on metabolic, cardiac, and neurological health.
Cardiovascular & Heart Health
- •Reduced Cardiac Events: Semaglutide and tirzepatide lower the combined risk of major adverse cardiovascular events (stroke, heart attack, cardiovascular death) by up to 13–18%.
- •Blood Pressure Lowering: Retatrutide trials show significant reductions in systolic blood pressure.
- •Heart Failure & Stroke: Associated with lower rates of heart failure.
Metabolic & Liver Health
- •Blood Sugar & Insulin Control: Originally developed for type 2 diabetes; stimulate insulin secretion when blood sugar is high and lower HbA1c, often putting pre-diabetes into remission.
- •Lipid Management: Substantial reductions in triglycerides and non-HDL cholesterol.
- •Fatty Liver Disease: All three (particularly retatrutide) show promise in reducing excess liver fat.
Neurological & Anti-Consumption Effects
- •Rewiring Reward Pathways: Targeting the brain's reward centers; being investigated as "anti-consumption" agents.
- •Reduced Addictive Behaviors: Observational reductions in food cravings, alcohol, nicotine, and compulsive behaviors.
Chronic Disease & Inflammation
- •Pain Reduction: Weight-independent improvements in knee osteoarthritis pain.
- •Sleep Apnea: Significant decreases in apnea-hypopnea index.
- •Kidney Protection: Evolving evidence links these agonists to lower risk of progressive kidney disease.
Pens vs Vials
Pens
- •Easier to use
- •More accurate dosing
- •Lower contamination risk
- •Better for beginners
- •Usually more expensive
Vials
- •Lower cost per mg
- •Flexible dosing
- •Require syringes
- •Require correct reconstitution if powdered
- •Higher risk of dosing mistakes or contamination if handled incorrectly